rdf:type |
|
lifeskim:mentions |
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0030705,
umls-concept:C0220847,
umls-concept:C0542341,
umls-concept:C0851347,
umls-concept:C0871261,
umls-concept:C1425475,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2003941,
umls-concept:C2911692
|
pubmed:issue |
2
|
pubmed:dateCreated |
2011-2-3
|
pubmed:abstractText |
We examined the association between IL28B single-nucleotide polymorphism rs12979860, hepatitis C virus (HCV) kinetic, and pegylated interferon alpha-2a pharmacodynamic parameters in HIV/HCV-coinfected patients from South America. Twenty-six subjects received pegylated interferon alpha-2a + ribavirin. Serum HCV-RNA and interferon concentrations were measured frequently during the first 12 weeks of therapy and analyzed using mathematical models. African Americans and whites had a similar distribution of IL28B genotypes (P = 0.5). The IL28B CC genotype was overrepresented (P = 0.015) in patients infected with HCV genotype-3 compared with genotype-1. In both genotype-1 and genotype-3, the first-phase viral decline and the average pegylated interferon-alpha-2a effectiveness during the first week of therapy were larger (trend P <= 0.12) in genotype-CC compared with genotypes-TC/TT. In genotype-1 patients, the second slower phase of viral decline (days 2-29) and infected cells loss rate, [delta], were larger (P = 0.02 and 0.11, respectively) in genotype-CC than in genotypes-TC/TT. These associations were not observed in genotype-3 patients.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/IL28B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a,
http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1944-7884
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
56
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
95-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:21157362-African Continental Ancestry Group,
pubmed-meshheading:21157362-Antiviral Agents,
pubmed-meshheading:21157362-European Continental Ancestry Group,
pubmed-meshheading:21157362-HIV Infections,
pubmed-meshheading:21157362-Hepatitis C, Chronic,
pubmed-meshheading:21157362-Humans,
pubmed-meshheading:21157362-Interferon-alpha,
pubmed-meshheading:21157362-Interleukins,
pubmed-meshheading:21157362-Models, Theoretical,
pubmed-meshheading:21157362-Polyethylene Glycols,
pubmed-meshheading:21157362-Polymorphism, Single Nucleotide,
pubmed-meshheading:21157362-RNA, Viral,
pubmed-meshheading:21157362-Recombinant Proteins,
pubmed-meshheading:21157362-Ribavirin,
pubmed-meshheading:21157362-Serum,
pubmed-meshheading:21157362-South America,
pubmed-meshheading:21157362-Viral Load
|
pubmed:year |
2011
|
pubmed:articleTitle |
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.
|
pubmed:affiliation |
Department of Infectious Diseases, University of São Paulo Hospital das Clínicas, São Paulo, Brazil. evaldostanislau@uol.com.br
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|